WO2022115053A1 - Multi-layered tablet formulation with extended release layer of metformin hydrochloride - Google Patents
Multi-layered tablet formulation with extended release layer of metformin hydrochloride Download PDFInfo
- Publication number
- WO2022115053A1 WO2022115053A1 PCT/TR2020/051186 TR2020051186W WO2022115053A1 WO 2022115053 A1 WO2022115053 A1 WO 2022115053A1 TR 2020051186 W TR2020051186 W TR 2020051186W WO 2022115053 A1 WO2022115053 A1 WO 2022115053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet formulation
- release layer
- layered tablet
- formulation according
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 238000013265 extended release Methods 0.000 title claims abstract description 34
- 238000009472 formulation Methods 0.000 title claims abstract description 23
- 229960004329 metformin hydrochloride Drugs 0.000 title claims abstract description 23
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000007942 layered tablet Substances 0.000 title claims abstract description 18
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims abstract description 19
- 229960003834 dapagliflozin Drugs 0.000 claims abstract description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 16
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000003607 modifier Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940069328 povidone Drugs 0.000 claims description 8
- 238000005550 wet granulation Methods 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 229960001866 silicon dioxide Drugs 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000000391 magnesium silicate Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 229940033134 talc Drugs 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- HIKIGWCXRDSDRC-UHFFFAOYSA-L disodium (E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].C(C=CC(=O)[O-])(=O)OCCCCCCCCCCCCCCCCCC.[Na+].C(CCCCCCCCCCCCCCCCC)OC(C=CC(=O)[O-])=O HIKIGWCXRDSDRC-UHFFFAOYSA-L 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- -1 gums Polymers 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920001592 potato starch Polymers 0.000 claims description 2
- 229940116317 potato starch Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000010410 layer Substances 0.000 description 33
- 229960003105 metformin Drugs 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- GOADIQFWSVMMRJ-UPGAGZFNSA-N dapagliflozin propanediol monohydrate Chemical compound O.C[C@H](O)CO.C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl GOADIQFWSVMMRJ-UPGAGZFNSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- WOSFAOJJPMFTRL-UHFFFAOYSA-N propane-1,1-diol hydrate Chemical compound O.CCC(O)O WOSFAOJJPMFTRL-UHFFFAOYSA-N 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 230000030558 renal glucose absorption Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940015903 xigduo Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Definitions
- the present invention relates to a multi-layered tablet formulation with an immediate release layer comprising dapagliflozin or a pharmaceutically acceptable salt thereof and an extended release layer comprising metformin hydrochloride and at least one pharmaceutically acceptable excipient for use in the treatment of the Type 2 diabetes.
- Diabetes is a group of metabolic disorder in which is related with high glucose in plasma.
- type 1, type 2, and gestational diabetes there is three types of diabetes, such as type 1, type 2, and gestational diabetes.
- type 2 diabetes is known to be the most common form of the diabetes in both of the developed and developing counties.
- Type 2 diabetes non-insulin dependent diabetes, (NIDDM)
- NIDDM non-insulin dependent diabetes, (NIDDM)
- NIDDM non-insulin dependent diabetes
- Diabetic microvascular complications and macro-vascular complications is the directly result of the degree of the sustained hyperglycemia.
- Type 2 diabetes is characterized by hyperglycemia and an increased risk of microvascular and macro- vascular complications.
- SGLT2 Sodium-glucose co-transporter-2
- Dapagliflozin is a first-in class compound which is a highly selective and orally active inhibitor of the human sodium-dependent glucose co-transporter 2 (SGLT2), and also is the major transporter responsible for renal glucose reabsorption from the turbula lumen. It inhibits the renal reabsorption of glucose and promotes excretion of excess glucose in the urine, thus it improves glycemic control in patients with Type 2 diabetes and lower glucose level in plasma.
- SGLT2 human sodium-dependent glucose co-transporter 2
- Dapagliflozin is (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol.
- the empirical formula of Dapagliflozin is C21H25CIO6 and its relative molecular mass is 408.87 mg/mole as a free base and 502.98 mg/mole as propanediol monohydrate salt.
- Dapagliflozin is a white to off-white powder, soluble in many polar organic solvents and non- hygroscopic.
- Metformin is an oral anti-hyperglycemic agent which has been widely used for improving glycemic control in patients with Type 2 diabetes for decades by being alone or combined form with other anti-hyperglycemic medications. Metformin can also be of value in the treatment of obese or overweight diabetic patients or in patients with polycystic ovary syndrome.
- Metformin can be taken in high doses in the range of 500 mg to 2500 mg per day and that requires twice or three times a day dosing. However, this type of administration may cause the changes in the blood concentration of the drug and that will trigger to expose the adverse reactions and resistance to the drug.
- Metformin can be associated with the adverse effects such as gastrointestinal symptoms, particularly diarrhea and nausea. In addition to that, it is largely eliminated unchanged by the kidneys and it can cause to be contraindicated in patients with renal disease or renal impairment. Thus, conventional administration has to be redesigned in order to lowering the adverse effects by reducing the frequency of administration required.
- Extended release formulations of Metformin have advantages over immediate release generates more uniform maintenance of blood plasma active drug concentrations and providing better patient compliance.
- EP2498758 relates to a bilayer tablet formulation comprising; Metformin hydrochloride as extended release form, sodium carboxymethyl cellulose as a binder; hydroxypropyl methylcellulose as a release modifier; magnesium stearate as a lubricant; and optionally silicon dioxide or colloidal silicon dioxide as a glidant presented in the first layer; Dapagliflozin (S) propylene glycol hydrate, fillers including microcrystalline cellulose and one or two additional fillers, crospovidone, silicon dioxide, and magnesium stearate presented in the second layer; and also optionally presented a film coating that covers the first layer and the second layer.
- Metformin hydrochloride as extended release form, sodium carboxymethyl cellulose as a binder
- hydroxypropyl methylcellulose as a release modifier
- magnesium stearate as a lubricant
- silicon dioxide or colloidal silicon dioxide as a glidant presented in the first layer
- EP3315124 relates to a bilayer tablet formulation
- a first layer which is composed of Metformin hydrochloride extended release form in an amount of 500 mg or 1000 mg, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, and optionally silicon dioxide or colloidal silicon dioxide;
- a second layer having a total weight of 300 mg to 400 mg, wherein it is composed of Dapagliflozin (S) propylene glycol hydrate in an amount of 2.5 mg, 5.0 mg or 10.0 mg, lactose anhydrous, microcrystalline cellulose, crospovidone, silicon dioxide, magnesium stearate, and optionally at least one of pregelatinized starch, hydroxypropyl cellulose and mannitol; and optionally a film coating that covers the first layer and the second layer.
- S Dapagliflozin
- W02020009352 relates to pharmaceutical formulation comprising Metformin in the core and amorphous Dapagliflozin L-proline in the coating layer.
- WO2013137839 relates to pharmaceutical formulation comprising extended-release Metformin hydrochloride in the core tablet and Dapagliflozin or pharmaceutically acceptable salts, solvates or hydrates thereof in the coating solution.
- the object of this invention is to provide a solid pharmaceutical formulation comprising therapeutically effective amounts of dapagliflozin or pharmaceutically acceptable salts thereof metformin hydrochloride as active ingredients which present different release profiles at individual layers.
- the present invention relates to provide a solid pharmaceutical formulation that can be manufactured as multi-layered tablet dosage form.
- Another object of the present invention is to develop a multi-layered tablet formulation comprising two formulation layers wherein one of them is immediate release layer, other one is extended release layer.
- Dapagliflozin or a pharmaceutically acceptable salt is presented in the immediate release layer and metformin hydrochloride is presented in the extended release layer.
- Another object of the present invention is to provide an extended release pharmaceutical formulation comprising Metformin hydrochloride manufactured by using wet granulation process.
- Another object of the present invention is to provide an extended release pharmaceutical formulation comprising Metformin hydrochloride as an active ingredient and at least one release modifier, disintegrant, binder, lubricant, glidant and solvent as pharmaceutically acceptable excipient.
- Another object of the present invention relates to an extended-release formulation comprising Metformin hydrochloride manufactured by using wet granulation process comprising the steps of: a) Metformin hydrochloride, Microcrystalline cellulose and specified amount of the Hydroxypropyl Methylcellulose are screened through a proper sieve and transferred high -shear ⁇ mixer to stir, b) Povidone is dissolved in sufficient quantity of water and added to the powder blend prepared in Step a to perform granulation process, c) The granule prepared in Step b is dried in fluid bed dryer and shifted through a proper sieve, d) The rest of the Hydroxypropyl Methylcellulose amount and Colloidal Silicon Dioxide are screened through a proper sieve and added to the granul
- Another object of the present invention is to provide a pharmaceutical formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof present in the immediate release layer and Metformin hydrochloride present in the extended release layer with povidone as binder and at least one pharmaceutically acceptable excipient wherein the hardness range of tablet obtained with extended release layer after compression is between 150 kP to 250 kP.
- the present invention provides solid pharmaceutical formulation comprising dapagliflozin or a pharmaceutically acceptable salt in immediate release layer and metformin hydrochloride in extended-release layer.
- immediate release refers to dosage forms disintegrate rapidly after administration with enhancing rate of dissolution. Moreover, in the case of solid dosage it should dissolve or disintegrate in the stomach within a short period. It should present rapid dissolution and absorption of drug, which may produce rapid onset of action. Therefore, in the present invention the immediate release layer is designed by considering the general literature knowledge.
- extended-release refers to dosage forms provide a longer duration of pharmacological response after administration of the dosage form than are ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount. Therefore, in the present invention is related to provide to form the extended release dosage form by using at least one pharmaceutically acceptable excipients.
- the extended release layer comprising metformin hydrochloride as an active ingredient with at least one pharmaceutically acceptable excipient is manufactured by using wet granulation process.
- Metformin is widely drug prescribed for lowering blood glucose in patients with Type 2 diabetes for decades. However, upon the necessity of administration in high doses in the range of 500 mg to 2500 mg per day, taking twice daily or three times a day is required.
- extended release layer comprising Metformin is necessary to improve the quality of therapy in patient with the type 2 diabetes.
- the extended release layer comprising metformin hydrochloride and at least one binder to overcome poor compressibility character of metformin during manufacturing, because the amount of metformin is very high due to dose per dosage form as it is presented in a range of 65 to 75% by weight per extended-release layer formulation.
- the proper binder is critical for obtaining a uniform granule with good compressibility characteristics.
- povidone is selected as a binder which is widely used in a variety of pharmaceutical formulations and it is primarily used in solid-dosage forms. Also, povidone solution prepared by dissolving it in a proper solvent is used as granulation solution in wet- granulation processes.
- the solvent may be selected from deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof.
- the solvent is deionized water.
- a preferred embodiment of the present invention is to provide extended release layer comprising metformin hydrochloride with povidone by using wet granulation process provided for the manufacture of tablets with at least one release modifier, disintegrant, lubricant and glidant.
- the release modifier is responsible for retarding of the prepared formulation by forming a gelling form.
- the selected release modifier is independent of pH, thus its mechanism does not depend on the pH of the environment it encounters.
- the release modifier may include, but are not limited to, hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, starches, gums, cellulose ethers, protein derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, polyvinylpyrrolidones, and cellulose acetate phthalate.
- PVA polyvinyl alcohol
- ethyl cellulose methacrylic polymers
- hydroxypropyl cellulose starches, gums, cellulose ethers, protein derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, polyvinylpyrrolidones, and cellulose acetate phthalate.
- at least one release modifier is Hydroxypropyl methylcellulose.
- the disintegrant may include, but are not limited to croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants.
- the disintegrant is Microcrystalline cellulose.
- the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant.
- the glidant is Colloidal silicon dioxide.
- the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, camauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants.
- the lubricant is Magnesium stearate.
- a solid pharmaceutical formulations are compressed into a multi-layered tablet form.
- the embodiment in accordance with the present invention is designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
- the embodiment identified as Example 1 is given in the Table- 1 below.
- Another object of the present invention relates to an extended release layer prepared by using wet granulation process providing the steps of: a) Metformin hydrochloride, Microcrystalline cellulose and specified amount of the Hydroxypropyl methylcellulose were screened through a proper sieve and transferred into high-shear mixer and stirred, b) Povidone was dissolved in sufficient quantity of water, then added to the prepared in Step a to perform granulation process, c) The granules prepared in Step b were dried in fluid bed dryer and screened through a proper sieve, d) The rest of the amount of Hydroxypropyl methylcellulose and Colloidal silicon dioxide were screened through a proper sieve and added to the granules prepared in Step c and stirred, e) Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step d and stirred to obtain a uniform final blend, f) Tablet compression is performed with the final blend in Step e.
- the flowability of final blend was good that leads tablet compression process to be achieved.
- tablet compression was performed to get tablets having hardness values between 150 kP to 250 kP.
- Example- la has the minimum hardness value
- Example- lb has the maximum hardness value.
- the dissolution test was carried out in pH 6.8 phosphate buffer. Other conditions are defined as; volume of dissolution media is 1000 ml, temperature of study is 37°C ⁇ 0.5, rotation speed is 100 rpm, USP apparatus is I (Basket).
- Table 2 The results of dissolution test conducted with Example 1 According to the results presented above, tablet hardness range which is between 150 kP to 250 kP is optimized to get proper dissolution profile.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a multi-layered tablet formulation with an immediate release layer comprising dapagliflozin or a pharmaceutically acceptable salt thereof and an extended release layer comprising metformin hydrochloride and at least one pharmaceutically acceptable excipient for use in the treatment of the Type 2 diabetes.
Description
MULTI-LAYERED TABLET FORMULATION WITH EXTENDED RELEASE LAYER OF METFORMIN HYDROCHLORIDE
FIELD OF INVENTION
The present invention relates to a multi-layered tablet formulation with an immediate release layer comprising dapagliflozin or a pharmaceutically acceptable salt thereof and an extended release layer comprising metformin hydrochloride and at least one pharmaceutically acceptable excipient for use in the treatment of the Type 2 diabetes.
BACKGROUND OF THE INVENTION
Diabetes is a group of metabolic disorder in which is related with high glucose in plasma. Currently, there is three types of diabetes, such as type 1, type 2, and gestational diabetes. However, type 2 diabetes is known to be the most common form of the diabetes in both of the developed and developing counties.
Type 2 diabetes (non-insulin dependent diabetes, (NIDDM)) is a condition and is called as insulin resistance where the body produces insulin, but certain mechanisms prevent insulin from moving glucose into cells. Therefore, glucose level rises to the unsafe in the blood and which is called as hyperglycemia.
Sustained hyperglycemia leads to worsen insulin resistance contributes to dysfunction in the beta cells of the pancreas. Diabetic microvascular complications and macro-vascular complications is the directly result of the degree of the sustained hyperglycemia. Thus, Type 2 diabetes is characterized by hyperglycemia and an increased risk of microvascular and macro- vascular complications.
In normal healthy individuals, glucose in plasma is filtered by glomerulus in the kidney and is actively reabsorbed in the proximal tube. However, Sodium-glucose co-transporter-2 (SGLT2) reabsorbs nearly all glucose at this site. Thus, a selective inhibitor of the SGLT2 in the kidney is essential to help the body retain glucose for its energy requirements.
Dapagliflozin is a first-in class compound which is a highly selective and orally active inhibitor of the human sodium-dependent glucose co-transporter 2 (SGLT2), and also is the major transporter responsible for renal glucose reabsorption from the turbula lumen. It inhibits the
renal reabsorption of glucose and promotes excretion of excess glucose in the urine, thus it improves glycemic control in patients with Type 2 diabetes and lower glucose level in plasma.
The chemical name of Dapagliflozin is (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4- ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol. The empirical formula of Dapagliflozin is C21H25CIO6 and its relative molecular mass is 408.87 mg/mole as a free base and 502.98 mg/mole as propanediol monohydrate salt.
Dapagliflozin is a white to off-white powder, soluble in many polar organic solvents and non- hygroscopic.
Metformin is an oral anti-hyperglycemic agent which has been widely used for improving glycemic control in patients with Type 2 diabetes for decades by being alone or combined form with other anti-hyperglycemic medications. Metformin can also be of value in the treatment of obese or overweight diabetic patients or in patients with polycystic ovary syndrome.
Metformin can be taken in high doses in the range of 500 mg to 2500 mg per day and that requires twice or three times a day dosing. However, this type of administration may cause the changes in the blood concentration of the drug and that will trigger to expose the adverse reactions and resistance to the drug.
According to the literature knowledge, Metformin can be associated with the adverse effects such as gastrointestinal symptoms, particularly diarrhea and nausea. In addition to that, it is largely eliminated unchanged by the kidneys and it can cause to be contraindicated in patients with renal disease or renal impairment. Thus, conventional administration has to be redesigned in order to lowering the adverse effects by reducing the frequency of administration required.
Extended release formulations of Metformin have advantages over immediate release generates more uniform maintenance of blood plasma active drug concentrations and providing better patient compliance.
Thus, Bristol-Myers Squibb and AstraZeneca developed another fixed dose combination of Dapagliflozin and Metformin for the treatment of the Type 2 diabetes, wherein Metformin is presented in the extended release formulation and Dapagliflozin is presented in the immediate release formulation. The fixed dose was firstly commercially authorized the U.S. It is currently marketed under the trade name of XIGDUO XR in the strengths of 2.5 mg/1000 mg, 5 mg/500 mg, 5 mg/ 1000 mg, 10 mg/500 mg and 10 mg/ 1000 mg per tablet.
In the state of art there are many patents/patent applications which are summarized below.
EP2498758 relates to a bilayer tablet formulation comprising; Metformin hydrochloride as extended release form, sodium carboxymethyl cellulose as a binder; hydroxypropyl methylcellulose as a release modifier; magnesium stearate as a lubricant; and optionally silicon dioxide or colloidal silicon dioxide as a glidant presented in the first layer; Dapagliflozin (S) propylene glycol hydrate, fillers including microcrystalline cellulose and one or two additional fillers, crospovidone, silicon dioxide, and magnesium stearate presented in the second layer; and also optionally presented a film coating that covers the first layer and the second layer.
EP3315124 relates to a bilayer tablet formulation comprising a first layer which is composed of Metformin hydrochloride extended release form in an amount of 500 mg or 1000 mg, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, and optionally silicon dioxide or colloidal silicon dioxide; a second layer having a total weight of 300 mg to 400 mg, wherein it is composed of Dapagliflozin (S) propylene glycol hydrate in an amount of 2.5 mg, 5.0 mg or 10.0 mg, lactose anhydrous, microcrystalline cellulose, crospovidone, silicon dioxide, magnesium stearate, and optionally at least one of pregelatinized starch, hydroxypropyl cellulose and mannitol; and optionally a film coating that covers the first layer and the second layer.
W02020009352 relates to pharmaceutical formulation comprising Metformin in the core and amorphous Dapagliflozin L-proline in the coating layer.
WO2013137839 relates to pharmaceutical formulation comprising extended-release Metformin hydrochloride in the core tablet and Dapagliflozin or pharmaceutically acceptable salts, solvates or hydrates thereof in the coating solution.
Many pharmaceutical compositions for pharmaceutical formulations comprising Dapagliflozin or one of its pharmaceutically acceptable salt thereof, in combination with Metformin hydrochloride are explained in the prior art documents stated above.
However, there is a need for a multi-layered tablet formulation composed of an immediate release layer comprising dapagliflozin or one of its pharmaceutically acceptable salt thereof and an extended-release layer comprising metformin hydrochloride and at least one pharmaceutically acceptable excipient that improves compressibility of the extended release layer.
Summary of the Invention
The object of this invention is to provide a solid pharmaceutical formulation comprising therapeutically effective amounts of dapagliflozin or pharmaceutically acceptable salts thereof metformin hydrochloride as active ingredients which present different release profiles at individual layers.
The present invention relates to provide a solid pharmaceutical formulation that can be manufactured as multi-layered tablet dosage form.
Another object of the present invention is to develop a multi-layered tablet formulation comprising two formulation layers wherein one of them is immediate release layer, other one is extended release layer.
Dapagliflozin or a pharmaceutically acceptable salt is presented in the immediate release layer and metformin hydrochloride is presented in the extended release layer.
Another object of the present invention is to provide an extended release pharmaceutical formulation comprising Metformin hydrochloride manufactured by using wet granulation process.
Another object of the present invention is to provide an extended release pharmaceutical formulation comprising Metformin hydrochloride as an active ingredient and at least one release modifier, disintegrant, binder, lubricant, glidant and solvent as pharmaceutically acceptable excipient. Another object of the present invention relates to an extended-release formulation comprising Metformin hydrochloride manufactured by using wet granulation process comprising the steps of: a) Metformin hydrochloride, Microcrystalline cellulose and specified amount of the Hydroxypropyl Methylcellulose are screened through a proper sieve and transferred high -shear· mixer to stir, b) Povidone is dissolved in sufficient quantity of water and added to the powder blend prepared in Step a to perform granulation process, c) The granule prepared in Step b is dried in fluid bed dryer and shifted through a proper sieve,
d) The rest of the Hydroxypropyl Methylcellulose amount and Colloidal Silicon Dioxide are screened through a proper sieve and added to the granules prepared in Step c and stirred, e) Magnesium stearate is screened through a proper sieve and added to the granules prepared in Step d and mixed to obtain a uniform final blend, f) Tablet compression is performed with the final blend in Step e.
Another object of the present invention is to provide a pharmaceutical formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof present in the immediate release layer and Metformin hydrochloride present in the extended release layer with povidone as binder and at least one pharmaceutically acceptable excipient wherein the hardness range of tablet obtained with extended release layer after compression is between 150 kP to 250 kP.
Detailed Description of the Invention
The present invention provides solid pharmaceutical formulation comprising dapagliflozin or a pharmaceutically acceptable salt in immediate release layer and metformin hydrochloride in extended-release layer.
The term an "immediate release" refers to dosage forms disintegrate rapidly after administration with enhancing rate of dissolution. Moreover, in the case of solid dosage it should dissolve or disintegrate in the stomach within a short period. It should present rapid dissolution and absorption of drug, which may produce rapid onset of action. Therefore, in the present invention the immediate release layer is designed by considering the general literature knowledge.
However, the term “extended-release” refers to dosage forms provide a longer duration of pharmacological response after administration of the dosage form than are ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount. Therefore, in the present invention is related to provide to form the extended release dosage form by using at least one pharmaceutically acceptable excipients.
The extended release layer comprising metformin hydrochloride as an active ingredient with at least one pharmaceutically acceptable excipient is manufactured by using wet granulation process.
Metformin is widely drug prescribed for lowering blood glucose in patients with Type 2 diabetes for decades. However, upon the necessity of administration in high doses in the range of 500 mg to 2500 mg per day, taking twice daily or three times a day is required.
Especially, gastrointestinal adverse effects are typically associated with Metformin. The combination with Dapagliflozin or any other related active substance does not lead to increase in the incidence of these adverse effects, which also helps to avoid observing adverse effects by reducing the frequency of administration method. Therefore, extended release layer comprising Metformin is necessary to improve the quality of therapy in patient with the type 2 diabetes. In the present invention, the extended release layer comprising metformin hydrochloride and at least one binder to overcome poor compressibility character of metformin during manufacturing, because the amount of metformin is very high due to dose per dosage form as it is presented in a range of 65 to 75% by weight per extended-release layer formulation. Thus, the proper binder is critical for obtaining a uniform granule with good compressibility characteristics.
In the present invention, since the compressibility is very important hardness of the tablet after the compression process should also be optimized.
In the present invention, povidone is selected as a binder which is widely used in a variety of pharmaceutical formulations and it is primarily used in solid-dosage forms. Also, povidone solution prepared by dissolving it in a proper solvent is used as granulation solution in wet- granulation processes.
In a preferred embodiment of the present invention, the solvent may be selected from deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof. Preferably, the solvent is deionized water. In a preferred embodiment of the present invention is to provide extended release layer comprising metformin hydrochloride with povidone by using wet granulation process provided for the manufacture of tablets with at least one release modifier, disintegrant, lubricant and glidant.
The release modifier is responsible for retarding of the prepared formulation by forming a gelling form. In the present invention, the selected release modifier is independent of pH, thus its mechanism does not depend on the pH of the environment it encounters.
In the preferred embodiment of the present invention, the release modifier may include, but are not limited to, hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, starches, gums, cellulose ethers, protein derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, polyvinylpyrrolidones, and cellulose acetate phthalate. Preferably, at least one release modifier is Hydroxypropyl methylcellulose. In the preferred embodiment of the present invention, the disintegrant may include, but are not limited to croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants. Preferably, the disintegrant is Microcrystalline cellulose. In the preferred embodiment of the present invention, the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant. Preferably, the glidant is Colloidal silicon dioxide.
In the preferred embodiment of the present invention, the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, camauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants. Preferably, the lubricant is Magnesium stearate.
In some embodiments of the present invention, a solid pharmaceutical formulations are compressed into a multi-layered tablet form. The embodiment in accordance with the present invention is designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
The embodiment identified as Example 1 is given in the Table- 1 below.
The proposed embodiment based on the invention with the amounts in w/w% of the extended- release layer composition are as stated below:
Another object of the present invention relates to an extended release layer prepared by using wet granulation process providing the steps of: a) Metformin hydrochloride, Microcrystalline cellulose and specified amount of the Hydroxypropyl methylcellulose were screened through a proper sieve and transferred into high-shear mixer and stirred, b) Povidone was dissolved in sufficient quantity of water, then added to the prepared in Step a to perform granulation process, c) The granules prepared in Step b were dried in fluid bed dryer and screened through a proper sieve, d) The rest of the amount of Hydroxypropyl methylcellulose and Colloidal silicon dioxide were screened through a proper sieve and added to the granules prepared in Step c and stirred, e) Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step d and stirred to obtain a uniform final blend, f) Tablet compression is performed with the final blend in Step e.
In the present invention, the flowability of final blend was good that leads tablet compression process to be achieved. Moreover, tablet compression was performed to get tablets having hardness values between 150 kP to 250 kP.
The prepared extended release layer was investigated for the determined qualitative and quantitative formulation of Example 1. The obtained tablets were subjected to dissolution test
which is one of the important analytical tests to characterize tablet properties and to achieve proper dissolution release profile for the tablet dosage form of the present invention. The comparative dissolution results of Example 1 with different hardness values were shown in Table 2. Example- la has the minimum hardness value, Example- lb has the maximum hardness value.
The dissolution test was carried out in pH 6.8 phosphate buffer. Other conditions are defined as; volume of dissolution media is 1000 ml, temperature of study is 37°C±0.5, rotation speed is 100 rpm, USP apparatus is I (Basket).
Table 2: The results of dissolution test conducted with Example 1
According to the results presented above, tablet hardness range which is between 150 kP to 250 kP is optimized to get proper dissolution profile.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims
1. A multi-layered-tablet formulation composed of an immediate release layer comprising dapagliflozin or a pharmaceutically acceptable salt thereof, an extended relaease layer comprising metformin hydrochloride and at least one pharmaceutically acceptable excipient, wherein; at least one pharmaceutically acceptable excipient present in the extended release layer is povidone as a binder, and the hardness value of extended release layer is between 150 to 250 kP.
2. A multi-layered tablet formulation according to claim 1, wherein the extended release layer is prepared by wet granulation method.
3. A multi-layered tablet formulation according to the preceding claims, wherein at least one pharmaceutically acceptable excipient present in the extended release layer is selected from a release modifier, a disintegrant, a lubricant, a glidant, a solvent and mixtures thereof.
4. A multi-layered tablet formulation according to claim 3, wherein the release modifier selected from hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, starches, gums, cellulose ethers, protein derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, polyvinylpyrrolidones, cellulose acetate phthalate and mixtures thereof.
5. A multi-layered tablet formulation according to Claim 3, wherein the disintegrant is selected from croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and mixtures thereof.
6. A multi-layered tablet formulation according to Claim 3, wherein the lubricant is selected from magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils, fats and mixtures thereof.
7. A multi-layered tablet formulation according to Claim 3, wherein the glidant is selected from silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and mixtures thereof.
8. A multi-layered tablet formulation according to Claim 3, wherein the solvent is selected from deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and mixtures thereof.
9. A multi-layered tablet formulation according to any of the preceding claims wherein the process for preparation of the extended-release layer comprises the steps of: a) Metformin hydrochloride, Microcrystalline cellulose and specified amount of the Hydroxypropyl Methylcellulose are screened through a proper sieve and transferred high-shear mixer to stir, b) Povidone is dissolved in sufficient quantity of water and added to the powder blend prepared in Step a to perform granulation process, c) The granule prepared in Step b is dried in fluid bed dryer and shifted through a proper sieve, d) The rest of the Hydroxypropyl Methylcellulose amount and Colloidal Silicon Dioxide are screened through a proper sieve and added to the granules prepared in Step c and stirred, e) Magnesium stearate is screened through a proper sieve and added to the granules prepared in Step d and mixed to obtain a uniform final blend, f) Tablet compression is performed with the final blend in Step e.
10. A multi-layered tablet formulation according to any one of the preceding claims for use in the treatment of the Type 2 diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2020/051186 WO2022115053A1 (en) | 2020-11-27 | 2020-11-27 | Multi-layered tablet formulation with extended release layer of metformin hydrochloride |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2020/051186 WO2022115053A1 (en) | 2020-11-27 | 2020-11-27 | Multi-layered tablet formulation with extended release layer of metformin hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022115053A1 true WO2022115053A1 (en) | 2022-06-02 |
Family
ID=81754734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2020/051186 WO2022115053A1 (en) | 2020-11-27 | 2020-11-27 | Multi-layered tablet formulation with extended release layer of metformin hydrochloride |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022115053A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115414347A (en) * | 2022-08-22 | 2022-12-02 | 北京诺和德美医药科技有限公司 | Sustained-release tablet and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
US20060088594A1 (en) * | 2004-10-08 | 2006-04-27 | Pilgaonkar Pratibha S | Highly compressible controlled delivery compositions of metformin |
WO2011060256A2 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
-
2020
- 2020-11-27 WO PCT/TR2020/051186 patent/WO2022115053A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
US20060088594A1 (en) * | 2004-10-08 | 2006-04-27 | Pilgaonkar Pratibha S | Highly compressible controlled delivery compositions of metformin |
WO2011060256A2 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
Non-Patent Citations (2)
Title |
---|
CHANDIRA MARGRET, B.S.VENKATESWARLU,JADHAVANUP SHANKARRAO, DEBJITBHOWMIK, B.JAYAKAR, T.V.NARAYANA: "Formulation and evaluation of extended release tablets containing metformin HCl", INTERNATIONAL JOURNAL OF CHEMTECH RESEARCH, vol. 2, no. 2, 1 January 2010 (2010-01-01), pages 1320 - 1329, XP055941698 * |
PATTANAYAK DURGA PRASAD, SUBASH C. DINDA: "Bilayer tablet formulation of metformin hydrochloride and glimepiride: A novel approach to improve therapeutic efficacy", INT J DRUG DISCOV HERB RES., 1 January 2011 (2011-01-01), pages 1 - 4, XP055941691, [retrieved on 20220712] * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115414347A (en) * | 2022-08-22 | 2022-12-02 | 北京诺和德美医药科技有限公司 | Sustained-release tablet and preparation method and application thereof |
CN115414347B (en) * | 2022-08-22 | 2023-09-15 | 北京诺和德美医药技术有限公司 | Sustained release tablet and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2568988T3 (en) | Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT | |
AU2015202718B2 (en) | Formulation for co-therapy treatment of diabetes | |
TW201125874A (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
AU2007297333A1 (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
WO2021086292A1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
EP4112047A1 (en) | Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin | |
WO2022115053A1 (en) | Multi-layered tablet formulation with extended release layer of metformin hydrochloride | |
KR20200078353A (en) | Pharmaceutical composition comprising empagliflozin and sitagliptin | |
CN106955273B (en) | Pharmaceutical composition containing sodium-glucose cotransporter 2 inhibitor | |
WO2024128997A1 (en) | Bilayer tablet composition with biphasic delivery system | |
TR2023006081T2 (en) | ENTERIC COATED DULOXETINE COMPOSITIONS | |
WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
EP4212150A1 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
WO2018122385A1 (en) | Pharmaceutical compositions of metformin hydrochloride and pioglitazone hydrochloride | |
WO2023136797A2 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
US20230255890A1 (en) | Composite formulation comprising sitagliptin and dapagliflozin and preparation method therefor | |
WO2022036506A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
WO2011126327A2 (en) | Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof | |
WO2024128996A1 (en) | Monolayer tablet composition of empagliflozin and metformin hydrochloride | |
JP2024522639A (en) | Oral preparations containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
US20240122858A1 (en) | Modified-release dosage forms of ruxolitinib | |
EP4008317A1 (en) | Solid pharmaceutical formulations of amorphous dapagliflozin | |
TR2021006927A2 (en) | A DOUBLE-LAYER TABLET FORMULATION CONTAINING AMORPHOUS DAPAGLIFLOZIN AND METFORMIN | |
JP2024524113A (en) | Oral combination tablet containing sitagliptin, dapagliflozin and metformin | |
WO2022119540A2 (en) | A process for formulations of dapagliflozin and metformin hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20963795 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023/006079 Country of ref document: TR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20963795 Country of ref document: EP Kind code of ref document: A1 |